In general, patients with resistant hypertension benefit from combination therapy with a renin‐angiotensin‐aldosterone system (RAAS) inhibitor such as an ACE inhibitor or ARB, calcium channel blocker, and a diuretic, but there is also evidence that beta‐blockers and vasodilators (especially in African American patients with chronic kidney disease) such as hydralazine can be very effective agents for blood pressure control [7]. The gene discussed is REN; the disease is chronic kidney disease.